ArticleFrontiers in oncology2023

Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers.

Gordon Cook et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.